Abstract
The mitogen-activated protein kinase (MAPK) signaling pathway plays a fundamental role in the carcinogenesis of colorectal and numerous other neoplasms. The development of targeted agents that inhibit MEK 1 and 2 has created the potential for downstream blockade of the MAPK pathway. Though MEK inhibition has demonstrated clinically significant efficacy in several tumor types, therapeutic success has been limited in colorectal cancer (CRC). This review will describe the current experience with MEK inhibition. It will also highlight ongoing efforts and future directions, including potential rational combination strategies and the investigation into potential predictive biomarkers of response.
Keywords: Colorectal Cancer, MAPK Pathway, MEK Inhibitor, Targeted Therapy.
Current Cancer Therapy Reviews
Title:Potential Role of MEK Inhibition in Treating Patients with Colorectal Cancer
Volume: 10 Issue: 1
Author(s): Paul Brittain, S. Gail Eckhardt and Christopher H. Lieu
Affiliation:
Keywords: Colorectal Cancer, MAPK Pathway, MEK Inhibitor, Targeted Therapy.
Abstract: The mitogen-activated protein kinase (MAPK) signaling pathway plays a fundamental role in the carcinogenesis of colorectal and numerous other neoplasms. The development of targeted agents that inhibit MEK 1 and 2 has created the potential for downstream blockade of the MAPK pathway. Though MEK inhibition has demonstrated clinically significant efficacy in several tumor types, therapeutic success has been limited in colorectal cancer (CRC). This review will describe the current experience with MEK inhibition. It will also highlight ongoing efforts and future directions, including potential rational combination strategies and the investigation into potential predictive biomarkers of response.
Export Options
About this article
Cite this article as:
Brittain Paul, Eckhardt Gail S. and Lieu H. Christopher, Potential Role of MEK Inhibition in Treating Patients with Colorectal Cancer, Current Cancer Therapy Reviews 2014; 10 (1) . https://dx.doi.org/10.2174/157339471001140815152055
DOI https://dx.doi.org/10.2174/157339471001140815152055 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardiovascular Effects of EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibodies
Cardiovascular & Hematological Agents in Medicinal Chemistry Bioactive Chromone Derivatives – Structural Diversity
Current Bioactive Compounds Colorectal Carcinogensis and Suppression of Tumor Development by Inhibition of Enzymes and Molecular Targets
Current Enzyme Inhibition Flavonoids in Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Clinical Efficacy and Effectiveness of Ursodeoxycholic Acid in Cholestatic Liver Diseases
Current Clinical Pharmacology The Contribution of Nitric Oxide and Carbon Monoxide to Neuronal Function and Development
Central Nervous System Agents in Medicinal Chemistry Targeting CSC-Related miRNAs for Cancer Therapy by Natural Agents
Current Drug Targets Intravitreal Injections and Diabetic Macular Edema: Actual and New Therapeutic Options
Current Diabetes Reviews Challenges in Managing Amniotic Fluid Embolism: An Up-to-Date Perspective on Diagnostic Testing with Focus on Novel Biomarkers and Avenues for Future Research
Current Pharmaceutical Biotechnology Q-TOF LC/MS-based Untargeted Metabolomics Approach to Evaluate the Effect of Folate-Conjugated Cyclodextrins on Triple-Negative Breast Cancer Cells
Current Pharmaceutical Analysis Compositions for Treatment of Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery Drug Resistance and Apoptosis in Cancer Treatment: Development of New Apoptosis-Inducing Agents Active in Drug Resistant Malignancies
Current Medicinal Chemistry - Anti-Cancer Agents Exploiting EPR in Polymer Drug Conjugate Delivery for Tumor Targeting
Current Pharmaceutical Design Identification of Protein Palmitoylation Inhibitors from a Scaffold Ranking Library
Combinatorial Chemistry & High Throughput Screening Molecular Targets for Nutritional Preemption of Cancer
Current Cancer Drug Targets Emergence of Functionalized Nanomedicines in Cancer Chemotherapy: Recent Advancements, Current Challenges and Toxicity Considerations
Recent Patents on Nanomedicine The Role of Connexins in Carcinogenesis: Review of Current Knowledge
Current Signal Transduction Therapy The Current View on the Helicase Activity of RNA Helicase A and Its Role in Gene Expression
Current Protein & Peptide Science The CLCA Gene Family: Putative Therapeutic Target for Respiratory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) A Cell Culture Model for the Assessment of the Chemopreventive Potential of Dietary Compounds.
Current Nutrition & Food Science